Fresenius SE & Co KGaA Registered Shares
FRE: XETR (DEU)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| @# | LOCK|kH^td | LOCK|xV#H&b# |
Fresenius SE Earnings: New Products Power Its Rejuvenate Strategy; Raise Fair Value Estimate 8%
Fresenius SE reported fourth-quarter 2025 organic sales growth of 7%, at the high end of its organic sales guidance, and ahead of company-compiled consensus, driven by both the Kabi and Helios segments. The EBIT increased 6% in constant currencies, in line with consensus.
